 |
| 18-Jul-14 | Reiterated |
Deutsche Bank |
Buy |
$144 → $149 |
|
| 23-Apr-14 | Reiterated |
Oppenheimer |
Perform |
$121 → $122 |
|
| 21-Mar-14 | Reiterated |
Barclays |
Equal Weight |
$115 → $130 |
|
| 31-Jan-14 | Reiterated |
Argus |
Buy |
$130 → $135 |
|
| 20-Nov-13 | Reiterated |
Deutsche Bank |
Buy |
$138 → $142 |
|
| 29-Aug-13 | Reiterated |
UBS |
Buy |
$121 → $124 |
|
| 27-Aug-13 | Reiterated |
Barclays |
Overweight |
$105 → $115 |
|
| 31-Jul-13 | Reiterated |
Oppenheimer |
Perform |
$100 → $109 |
|
| 24-Apr-13 | Reiterated |
Deutsche Bank |
Buy |
$108 → $115 |
|
| 15-Apr-13 | Reiterated |
Barclays |
Equal Weight |
$90 → $105 |
|
| 08-Apr-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$95 → $105 |
|
| 25-Jan-13 | Upgrade |
Argus |
Hold → Buy |
$96 |
|
| 24-Jan-13 | Reiterated |
UBS |
Buy |
$96 → $98 |
|
| 12-Sep-12 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$84 |
|
| 10-Sep-12 | Upgrade |
UBS |
Neutral → Buy |
$80 → $96 |
|
| 02-Aug-12 | Downgrade |
Argus |
Buy → Hold |
|
|
| 15-Mar-12 | Resumed |
Stifel Nicolaus |
Hold |
|
|
| 09-Feb-12 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 09-Sep-11 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 10-May-11 | Reiterated |
MP Advisors |
Outperform |
$63 → $65 |
|
|
|
| 22-Jul-14 06:13AM | [$$] 9 Health Care Stocks From Index-Crushing Fund at Barrons.com |
| 21-Jul-14 03:11PM | Astellas Up on Pipeline Update, Oncology in Focus (revised) Zacks |
| 01:15PM | Amgen's AMG 416 Succeeds in Phase III, Shares Up Zacks |
| 18-Jul-14 03:40PM | Biotech Enters Reporting Season With Large Caps Central To Sector Performance Benzinga |
| 07:26AM | Amgen: Grappling With The Reality Of Patent Expiries at Seeking Alpha |
| 17-Jul-14 05:52PM | Amgen parathyroid drug found effective in kidney patient trial Reuters |
| 05:32PM | [$$] Amgen Hormone Drug Proves Positive in Study at The Wall Street Journal |
| 04:29PM | Amgen thyroid drug succeeds in late stage kidney patient trial Reuters |
| 04:01PM | Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis PR Newswire |
| 16-Jul-14 02:50PM | Astellas Up on Pipeline Update, Oncology in Focus Zacks |
| 10:15AM | 4 Top Biotechs Expected to Beat Earnings Expectations at 24/7 Wall St. |
| 15-Jul-14 02:24PM | Q2 2014 Update: My Whistler Income And Growth Portfolio at Seeking Alpha |
| 11:21AM | Amgen (AMGN) Roof Leaking Today at TheStreet |
| 10:33AM | Facebook, Twitter slip following cautious valuation comments from Fed at theflyonthewall.com |
| 14-Jul-14 01:14PM | 3 Stocks Reiterated As A Buy: AXP, BIDU, AMGN at TheStreet |
| 10-Jul-14 08:20AM | The Zacks Analyst Blog Highlights: Regado Biosciences, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi and Amgen Zacks |
| 09-Jul-14 11:52AM | Celgene Drug Otezla Fails Trial, But Street Sanguine at Investor's Business Daily |
| 08-Jul-14 02:42PM | Alexion Pharma Looks To Life Beyond Its Blockbuster at Investor's Business Daily |
| 10:03AM | Gilead Sciences: How Big a Beat? at Barrons.com |
| 08:54AM | Story Stocks from Briefing.com Briefing.com |
| 08:39AM | Story Stocks from Briefing.com Briefing.com |
| 07-Jul-14 10:28AM | Story Stocks from Briefing.com Briefing.com |
| 09:48AM | Story Stocks from Briefing.com Briefing.com |
| 09:17AM | Story Stocks from Briefing.com Briefing.com |
| 08:46AM | Story Stocks from Briefing.com Briefing.com |
| 03-Jul-14 03:30PM | BIND Therapeutics Ends Oncology Deal with Amgen Zacks |
| 12:38PM | Gilead Sciences: Time for an Earnings Beat? at Barrons.com |
| 12:26PM | Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector Benzinga |
| 12:17PM | Story Stocks from Briefing.com Briefing.com |
| 12:04PM | Ligand Pharmaceuticals: Appendix at Seeking Alpha |
| 11:31AM | Bind Therapeutics Down After Losing Amgen Partnership at Investor's Business Daily |
| 10:41AM | Dow Hits 17,000 On Jobs Report; Walgreen Same-Store-Sales Surge 7.5% Benzinga |
| 10:35AM | Interested In Healthcare Stocks? Look At This ETF at Investopedia |
| 10:07AM | Stocks to Watch: Lululemon, Bind Therapeutics, Regado Biosciences at The Wall Street Journal |
| 09:18AM | Why Bind Therapeutics (BIND) Stock Is Down in Pre-Market Trading Today at TheStreet |
| 07:52AM | Early movers: APP, MS, LULU, BIND, ABBV & more at CNBC |
| 07:15AM | Story Stocks from Briefing.com Briefing.com |
| 02-Jul-14 05:55PM | Bind Therapeutics ends cancer drug partnership with Amgen Reuters |
| 05:10PM | Why BIND Therapeutics (BIND) Stock Is Falling In After-Hours Trading Today at TheStreet |
| 05:02PM | 3 Dividend Stocks for Summer: Amgen, Healthcare Services Group, and Quality Systems at Motley Fool |
| 04:55PM | Amgen Gets Breakthrough Therapy Status for Leukemia Drug Zacks |
| 05:00AM | 'Fast Money' Recap: Let Your Winning Trades Keep Running at TheStreet |
| 01-Jul-14 09:23AM | [$$] Amgen's Leukemia Drug Gets Breakthrough Designation at The Wall Street Journal |
| 08:09AM | Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia PR Newswire |
| 30-Jun-14 03:16PM | Amgen Inc. Bonds: A Rare Combination Of Low Risk And High Value at Seeking Alpha |
| 28-Jun-14 12:01AM | [$$] The World's Most Respected Companies at Barrons.com |
| 26-Jun-14 09:02AM | Will Amgens Acquisition of Onyx Pay off Soon? at Motley Fool |
| 09:02AM | Will Amgens Acquisition of Onyx Pay off Soon? |
| 23-Jun-14 08:01PM | Biotech R&D spending outpaces revenue growth-report Reuters |
| 08:01PM | Biotech R&D spending outpaces revenue growth-report |
| 12:55PM | Supreme Court Erects Obstacle to Class Actions for Securities Fraud |
| 12:55PM | Supreme Court Adds New Hurdle in Investors Class-Action Suits |
| 12:55PM | New Hurdle in Investors Class Actions at New York Times |
| 12:55PM | New Hurdle In Investors Class Actions |
| 12:55PM | New Hurdle in Investors Class Actions |
| 11:52AM | Tired of Paltry Junk-Bond Yields? Try These Alternatives at The Wall Street Journal |
| 11:52AM | Tired of Paltry Junk-Bond Yields? Try These Alternatives |
| 19-Jun-14 03:10PM | [$$] Cancer Doctors Ring Up Big Bills for Tarnished Drug at The Wall Street Journal |
| 02:50PM | [$$] Cancer Doctors Ring Up Big Bills for Tarnished Drug at The Wall Street Journal |
| 16-Jun-14 05:32PM | 3 Undervalued Amgen Growth Opportunities to Watch at Motley Fool |
| 05:32PM | 3 Undervalued Amgen Growth Opportunities to Watch |
| 04:03PM | Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer PR Newswire |
| 04:03PM | Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer |
| 15-Jun-14 01:10PM | Is Gene Therapy Medicine's Next Big Thing? at Motley Fool |
| 13-Jun-14 03:34PM | Is Amgen's Dividend Safe? at Motley Fool |
| 03:34PM | Is Amgen's Dividend Safe? |
| 08:03AM | What Will Happen When Biotech Drugs Go Generic? at Forbes |
| 08:03AM | What Will Happen When Biotech Drugs Go Generic? |
| 07:42AM | The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and AmgenThe Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen Zacks |
| 07:42AM | The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and AmgenThe Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen |
| 12-Jun-14 06:19PM | OFFICIAL - UPDATE 3-U.S. investigating Icahn, Mickelson in insider trading probe-source Reuters |
| 06:19PM | OFFICIAL - UPDATE 3-U.S. investigating Icahn, Mickelson in insider trading probe-source |
| 04:10PM | Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement Zacks |
| 04:10PM | Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement |
| 02:12PM | Sharp Scrutiny From European Medicines Agency Of Amgen And Servier Heart Drug at Forbes |
| 02:12PM | Sharp Scrutiny From European Medicines Agency Of Amgen And Servier Heart Drug |
| 01:18PM | US tech and pharma park cash offshore at Financial Times |
| 12:57PM | InterMune Up On Bullish View Of U.S. Esbriet Launch at Investor's Business Daily |
| 12:57PM | InterMune Up On Bullish View Of U.S. Esbriet Launch |
| 05:10AM | Is AbbVie's Dividend Safe? at Motley Fool |
| 11-Jun-14 08:19PM | Amgen (AMGN) Management Presents at Goldman Sachs 35th Annual Global Healthcare Conference (Transcript) Seeking Alpha |
| 05:19PM | Amgen says Phase 2 study of brodalumab met primary endpoint theflyonthewall.com |
| 05:19PM | Amgen says Phase 2 study of brodalumab met primary endpoint |
| 05:00PM | Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine PR Newswire |
| 05:00PM | Amgen psoriatic arthritis drug maintains efficacy after 1 yr -study Reuters |
| 10:58AM | BIND Therapeutics Set To Revolutionize Drug Treatment As Clinical Data Continues To Impress at Seeking Alpha |
| 10-Jun-14 01:04PM | 3M's Loss is Amgen's Gain at Barrons.com |
| 09:20AM | UPDATE: Morgan Stanley Reiterates On Amgen On New CFO Benzinga |
| 06:05AM | [$$] MacroGenics Looks Immune to Downside at Barrons.com |
| 09-Jun-14 05:41PM | [$$] 3M Finance Chief Departs for Amgen at The Wall Street Journal |
| 04:34PM | AMGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online |
| 04:22PM | Amgen names former 3M CFO Meline as finance chief Reuters |
| 04:15PM | Amgen Appoints David W. Meline Executive Vice President and Chief Financial Officer PR Newswire |
| 07-Jun-14 11:06AM | 3 Spectacular Ways Samsung Could Disrupt the Health Care Industry at Motley Fool |
| 06-Jun-14 04:15PM | Amgen To Present At The Goldman Sachs Global Healthcare Conference PR Newswire |
| 05-Jun-14 06:31PM | 2 Reasons to Watch Amgen, Inc. at Motley Fool |
| 07:36AM | The Zacks Analyst Blog Highlights: Pharmacyclics, AbbVie, Gilead, Amgen and Celgene. Zacks |
| 04-Jun-14 05:04PM | Whither Amgen? A Split Is Suggested for the Biotech at The Wall Street Journal |
| 04:19PM | Whither Amgen? A Split is Suggested for the Biotech at The Wall Street Journal |
| 10:31AM | Time to Break Up Amgen? at Barrons.com |
|
|
| Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Dittrich Thomas J.W. | VP, Finance & CAO | May 21 | Option Exercise | 56.64 | 4,130 | 233,911 | 22,719 | May 22 05:15 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 21 | Sale | 112.83 | 4,130 | 465,984 | 18,589 | May 22 05:15 PM | | Bradway Robert A | Chairman, CEO and President | May 12 | Buy | 111.77 | 894 | 99,919 | 185,013 | May 12 08:33 PM | | Michael A Kelly | Acting CFO | Apr 28 | Sale | 110.45 | 2,065 | 228,072 | 41,041 | Apr 29 05:48 PM | | de Carbonnel Francois | Director | Mar 06 | Option Exercise | 54.44 | 10,000 | 544,350 | 25,364 | Mar 07 05:23 PM | | de Carbonnel Francois | Director | Mar 06 | Sale | 126.69 | 1,000 | 126,690 | 18,343 | Mar 07 05:23 PM | | BALTIMORE DAVID | Director | Feb 26 | Option Exercise | 62.55 | 5,000 | 312,750 | 31,879 | Feb 26 08:28 PM | | HENDERSON REBECCA M | Director | Feb 13 | Option Exercise | 62.41 | 20,000 | 1,248,160 | 25,549 | Feb 14 04:34 PM | | HENDERSON REBECCA M | Director | Feb 13 | Sale | 123.53 | 20,000 | 2,470,680 | 5,549 | Feb 14 04:34 PM | | Bradway Robert A | Chairman, CEO and President | Feb 12 | Option Exercise | 62.55 | 65,000 | 4,065,750 | 216,040 | Feb 14 04:19 PM | | AMGEN INC | 10% Owner | Dec 17 | Buy | 7.00 | 272,142 | 1,904,994 | 541,399 | Dec 18 06:09 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Option Exercise | 58.43 | 18,000 | 1,051,740 | 59,133 | Sep 05 07:33 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Sale | 112.76 | 18,000 | 2,029,768 | 34,851 | Sep 05 07:33 PM | | BALTIMORE DAVID | Director | Aug 28 | Sale | 109.66 | 4,582 | 502,462 | 27,789 | Aug 30 05:36 PM |
|
|
|
|
|
|
